Itraxyl

Such concerns may be experienced due to the long-term use of Itraconazole, the active ingredient of Itraxtyl, with the classical treatment approach, especially in dermatological fungal infections. However, Itraxyl does not have negative effects on the liver with the application of cure therapy. In a clinical study conducted in 2002, AST, ALT, Alkaline Phosphatase and Total Bilirubin tests were monitored in patients treated with Itraconazole (Cure) Pulse. Itraconazole has been found to be safe in terms of its effects on the liver.

Such questions may be asked due to the drug interactions of Itraconazole in polypharmacy, that is, in the elderly who are administered more than one drug. There is no harm in using Itraxyl in the elderly. There are also clinical studies on the suitability and efficacy of itraconazole for use in the elderly. Itraconazole is effective and safe in the elderly.

After itraconazole settles in the tissue, its excretion occurs with the tissue renewing itself. Thanks to its high Keratinophilic and Lipophilic properties, itraconazole stays in the target tissue for a long time, allowing cure therapy. Cure (Pulse) Treatment: It is a form of treatment that reduces both the total amount of drug taken and the cost due to itraconazole staying in the tissues for a long time. One-cure treatment is administered as a 3-week break after using 2x2 (400mg/day) doses of medication for one week. Especially in dermatological fungal infections such as Onychomycosis, instead of the classical treatment approach that takes a long time and requires monitoring of liver enzymes, effective and reliable treatment is provided with less and shorter-term drug use, thanks to the application of Itraconazole cure therapy, which also eliminates the necessity of examination.

The antifungal agent, which remains in therapeutic concentration for a long time in the infected tissue, provides effective treatment. While itraconazole stays in the nail tissue for 9 months, Terbinafine can only stay for 6 months. In addition, according to a clinical study, the clinical improvement rate in patients treated with Itraconazole cure therapy in the treatment of onychomycosis was 77%, while this rate was only 68% in patients who used 250 mg of Terbinafine every day for 3 months. In addition, the rate of discontinuation of the treatment due to the side effects experienced due to the same study was 12% in the patients using Terbinafine, while none of the patients in the Itraconazole group discontinued the treatment.

In-vitro studies have shown that Terbinafine inhibits CYP2D6 (Cytochrome P450 2D6)-related metabolism. The Cytochrome P450 enzyme responsible for the oxidative metabolism of approximately 25% of drugs is CYP2D6. CYP2D6 plays a role in the metabolism of many drugs that have a narrow therapeutic index and thus may cause drug therapy to fail or toxic reactions to occur more easily. Caution is required when using terbinafine together with tricyclic antidepressants, beta blockers, SSRIs (selective serotonin reuptake inhibitors) metabolized by this enzyme. As can be seen, drugs that interact with Terbinafine are widely used in our country. In addition, Terbinafine is used in the continuous treatment of dermatological fungal diseases. Patients who are treated with polypharmacy, that is, many drugs, during the drug use period with a long treatment period, should be followed carefully.

In the treatment of oral candidiasis, Itraxyl 100mg once daily for 15 days. Must be used with posology

The absorption of itraconazole is also reduced when stomach acid decreases. If Itraxyl needs to be used together with drugs that reduce stomach acidity, such as antacids and PPI (proton pump inhibitor) group drugs, it is recommended that these drugs be taken at least 2 hours after taking Itraxyl.

There are no studies on the use of itraconazole in pregnant women. Itraxyl is pregnancy category C. In women of childbearing age, appropriate contraceptive methods should be used from the end of itraconazole treatment until the next menstrual period. It can be recommended to be used in pregnant women only in life-threatening systemic mycoses, in cases where the benefit outweighs the possible risks to the fetus, according to the physician's decision.

Patient follow-up is not required in patients treated with a course of Itraxyl therapy. In patients on continuous therapy with terbinafine, there is a need for monitoring of AST and ALT levels, which are complete blood count and liver enzyme tests, every 4-6 weeks.

It is often difficult to detect the pathogen in both gynecological and dermatological fungal infections. In cases where the pathogen cannot be detected, Itraxyl is the first choice treatment agent with its broad spectrum of action. Thanks to the broad spectrum of action of Itraxyl, it provides effective treatment in mixed infections.

Since clinical studies on the use of itraconazole in children are limited, its use in children is not recommended unless the potential benefit outweighs the potential risk. Information on some pediatric daily dose applications, which are applied when the physician deems it necessary, are stated in the literature.

There is no need for co-treatment in vaginal candidiasis. Co-treatment in the treatment of gynecological fungal infections is not supported by clinical circles. The main mode of transmission of gynecological fungal infections is the normal flora of the person and the gastrointestinal tract, rather than sexual intercourse. There is no need for co-treatment with Itraxyl in the treatment of gynecological fungal diseases. However, the physician who will administer the treatment can apply the spouse treatment according to the condition of the patient.

Clinical studies prove that itraconazole is effective in chronic and recurrent gynecological fungal infections. Although different treatment protocols can be applied in these clinical studies, it is generally recommended to use the initial dose as 2x2 for one day and then 2x2 per day on the first day of each menstrual cycle for 6 months for prophylaxis. It was observed that up to 85% clinical and mycological improvement was achieved in chronic and recurrent vaginal yeast infections with itraconazole at the end of this treatment method, which was applied for 6 months. These studies support the use of itraconazole in chronic and recurrent vaginal yeast infections. There is no relevant posology in the approved propositions of itraconazole containing products. In the light of the literature, we can transfer these scientific data to physicians who ask about the effectiveness of Itraconazole in chronic and recurrent vaginal yeast infections.

mixed infections; are infections where more than one pathogen such as bacteria, protozoa and fungi coexist. In cases where Ornidazole and Itraconazole should be used together; As stated in the posology of itraconazole for 1 day (2x2) vulvovaginal candiasis; The application of Ornidazole in the form of a 5-day treatment (2x1) is the generally accepted method of application.